Vanguard Capital Management’s Ginkgo Bioworks DNA Stock Holding History
Bought
Maintained
Sold
Other funds holding DNA
Vanguard Capital Management's DNA Position: Q3 2026 in Review
Vanguard Capital Management increased its Ginkgo Bioworks (DNA) stake by 1.1% in Q3 2026, buying an estimated $185K and bringing the position to 2,109,962 shares worth $27.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2232.
Vanguard Capital Management first reported a position in DNA in Q1 2026 and has held it in 3 quarters since. 183 funds tracked by Wall St. Rank hold DNA as of Q3 2026.
- Vanguard Capital Management held 2,109,962 shares of Ginkgo Bioworks worth $27.1M as of Q3 2026.
- Vanguard Capital Management bought 22,669 Ginkgo Bioworks shares in Q3 2026, an estimated $185K.
- Ginkgo Bioworks made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2232 holding.
- Vanguard Capital Management first reported a position in Ginkgo Bioworks in Q1 2026 and has held it in 3 quarters since.
- 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.